Dephospho-Uncarboxylated Matrix Gla-Protein Is Associated With Adverse Outcomes in Heart Failure

Area of Science:

• Cardiovascular Medicine
• Proteomics
• Biochemistry

Background:

• Matrix Gla-protein (MGP) is vital for preventing vascular calcification, requiring vitamin K-dependent carboxylation for activation.
• Elevated levels of inactive MGP (dpucMGP) correlate with arterial stiffening and reduced muscle mass in heart failure (HF).
• The prognostic significance of dpucMGP in HF patients remains unclear.

Purpose of the Study:

• To investigate the association between plasma dpucMGP levels and adverse clinical outcomes in a large cohort of HF patients.
• To explore the proteomic associations of dpucMGP and identify related biological pathways.
• To determine if dpucMGP levels mediate the relationship between warfarin use and adverse outcomes in HF.

Main Methods:

• Plasma dpucMGP was measured in 2247 participants of the Penn HF Study (PHFS).
• Proteomic analysis (SomaScan assay) identified ~5000 proteins associated with dpucMGP.
• Associations between dpucMGP and risks of death or HF-related hospital admission, and all-cause death were assessed.

Main Results:

• Higher dpucMGP levels were significantly associated with increased risks of death or HF-related hospital admission (SHR 1.23) and all-cause death (SHR 1.32).
• dpucMGP showed proteomic links to acute phase response, coagulation, complement, fibrosis, cell signaling, and metabolic pathways.
• Higher dpucMGP mediated the association between warfarin use and adverse outcomes, particularly in nonischemic HF.

Conclusions:

• Elevated dpucMGP is a significant predictor of adverse outcomes in HF patients.
• dpucMGP is implicated in various biological pathways and mediates warfarin's adverse effects.
• Further research is needed to explore therapeutic strategies targeting dpucMGP reduction in HF.